Cancer kills roughly 9.7 million people worldwide each year, making it the second leading cause of death globally. But the word “cancer” covers more than 200 distinct diseases, and their deadliness varies enormously. Some carry five-year survival rates above 90%, while others remain below 15%. The overall five-year relative survival rate for all cancers combined in the United States is now 70.5%, meaning roughly seven in ten people diagnosed today will be alive five years later.
That number has climbed significantly. In 1990, it was closer to 59%. The cancer death rate in the U.S. has dropped 34% since its peak in 1991, a decline the American Cancer Society estimates has averted approximately 4.5 million deaths.
The Deadliest Types of Cancer
The cancers with the lowest survival rates tend to share a pattern: they’re difficult to detect early and often grow in or near vital organs. Pancreatic cancer sits at the bottom, with a five-year survival rate of just 13.7%. It typically causes few symptoms until it has already spread, which is why most cases are diagnosed at an advanced stage.
The other cancers with the poorest outcomes include:
- Liver cancer: 21.9% five-year survival
- Esophageal cancer: 22.2%
- Lung cancer: 29.5%
- Brain cancer: 32.9%
Lung cancer deserves special attention because of its sheer scale. While its survival rate has improved in recent years, it still kills more Americans than any other cancer simply because so many people are diagnosed with it. Brain cancers, meanwhile, are especially difficult to treat because surgery in or near the brain carries unique risks, and many drugs struggle to reach tumors there.
Cancers With High Survival Rates
Not all cancers are a death sentence, and the gap between the most and least survivable types is enormous. Thyroid cancer, prostate cancer, and testicular cancer all have five-year survival rates well above 90% when caught at a localized stage. Breast cancer survival has also improved dramatically, with localized cases carrying survival rates near 99%.
The single biggest factor in whether a cancer is survivable is stage at diagnosis. A cancer detected before it spreads beyond its original site is far easier to treat than one that has reached distant organs. This is why screening programs for breast, cervical, colon, and lung cancers have had such a measurable effect on death rates. Catching the disease early moves a patient from the worst survival statistics into the best.
How Cancer Actually Causes Death
Cancer doesn’t kill in one uniform way. The specific mechanism depends on where the disease grows, how far it spreads, and which organs it disrupts. Understanding this helps explain why some cancers are so much more dangerous than others.
One common pathway is organ failure. A tumor growing in the liver, for example, can disrupt the organ’s ability to filter toxins and maintain the body’s chemical balance. When the liver can no longer keep up, the imbalance becomes life-threatening. Similarly, cancer that blocks the lungs reduces the body’s ability to absorb oxygen, and a weakened patient may not be able to fight off a resulting lung infection even with strong antibiotics.
Cancer in the digestive system can physically block the intestines, preventing the body from absorbing nutrients and calories. This starvation effect weakens the immune system and leaves the body unable to cope with infections or other complications. Cancer that spreads to the bones can release excess calcium into the bloodstream, overwhelming the body’s ability to correct the imbalance. And when cancer invades the bone marrow, the body gradually loses its ability to produce red blood cells (which carry oxygen), white blood cells (which fight infection), and platelets (which stop bleeding). Tumors can also grow directly into blood vessels in critical areas, causing dangerous internal bleeding.
How Treatment Has Changed the Numbers
The decline in cancer mortality over the past three decades reflects real advances in treatment, not just earlier detection. One striking example is advanced melanoma, the most dangerous form of skin cancer. In 2011, a patient diagnosed with melanoma that had already spread to distant organs had a median survival of just six and a half months. The condition was nearly universally fatal.
Then immunotherapy changed the picture. A class of drugs called immune checkpoint inhibitors, which essentially remove the brakes on the immune system so it can attack cancer cells, transformed outcomes. A major trial following 945 patients across 21 countries found that a combination of two such drugs pushed median survival past six years. Half of patients treated with this combination are now expected to live ten years or longer without dying from their disease. Patients who remain cancer-free at three years have a high likelihood of staying that way at the ten-year mark.
Childhood cancer tells a similar story. In the mid-1970s, 58% of children diagnosed with cancer survived at least five years. Today that figure ranges from 83% to 88% depending on age group. For childhood leukemia specifically, the most common pediatric cancer, five-year survival rose from 57% in 1975 to over 92%. Non-Hodgkin lymphoma in children went from 43% to over 91% in the same period.
What Determines Your Individual Risk
Population-level survival statistics are useful for understanding the big picture, but they’re averages that blend together early-stage and late-stage cases, younger and older patients, and people with varying overall health. Your individual outlook depends on several factors working together.
Stage at diagnosis matters most. A localized cancer and the same cancer diagnosed after it has spread to distant organs can have survival rates that differ by 50 percentage points or more. Age plays a role because younger patients generally tolerate aggressive treatment better and have fewer competing health conditions. The specific biology of the tumor, including how fast it grows and whether it carries genetic mutations that make it responsive to targeted drugs, also shapes outcomes.
The type of cancer is the starting variable. A stage IV pancreatic cancer and a stage IV thyroid cancer are both advanced, but they behave very differently and carry very different prognoses. “Cancer” as a single category is almost too broad to be meaningful when it comes to predicting how dangerous any one diagnosis will be.